Erika G Martin1, Colleen L Barry. 1. Rockefeller College of Public Affairs & Policy, University at Albany, State University of New York, Albany, NY 12222, USA. emartin@albany.edu
Abstract
OBJECTIVES: We sought state-level factors associated with the adoption of medications to treat mental health conditions on state formularies for the AIDS Drug Assistance Program. METHODS: We interviewed 22 state and national program experts and identified 7 state-level factors: case burden, federal dollar-per-case Ryan White allocation size, political orientation, state wealth, passage of a mental health parity law, number of psychiatrists per population, and size of mental health budget. We then used survival analysis to test whether the factors were associated with faster adoption of psychotropic drugs from 1997 to 2008. RESULTS: The relative size of a state's federal Ryan White HIV/AIDS Program allocation, the state's political orientation, and its concentration of psychiatrists were significantly associated with time-to-adoption of psychotropic drugs on state AIDS Drug Assistance Program formularies. CONCLUSIONS: Substantial heterogeneity exists across states in formulary adoption of drugs to treat mental illness. Understanding what factors contribute to variation in adoption is vital given the importance of treating mental health conditions as a component of comprehensive HIV care.
OBJECTIVES: We sought state-level factors associated with the adoption of medications to treat mental health conditions on state formularies for the AIDS Drug Assistance Program. METHODS: We interviewed 22 state and national program experts and identified 7 state-level factors: case burden, federal dollar-per-case Ryan White allocation size, political orientation, state wealth, passage of a mental health parity law, number of psychiatrists per population, and size of mental health budget. We then used survival analysis to test whether the factors were associated with faster adoption of psychotropic drugs from 1997 to 2008. RESULTS: The relative size of a state's federal Ryan White HIV/AIDS Program allocation, the state's political orientation, and its concentration of psychiatrists were significantly associated with time-to-adoption of psychotropic drugs on state AIDS Drug Assistance Program formularies. CONCLUSIONS: Substantial heterogeneity exists across states in formulary adoption of drugs to treat mental illness. Understanding what factors contribute to variation in adoption is vital given the importance of treating mental health conditions as a component of comprehensive HIV care.
Authors: W E Cunningham; L E Markson; R M Andersen; S H Crystal; J A Fleishman; C Golin; A Gifford; H H Liu; T T Nakazono; S Morton; S A Bozzette; M F Shapiro; N S Wenger Journal: J Acquir Immune Defic Syndr Date: 2000-10-01 Impact factor: 3.731
Authors: Mary K Tegger; Heidi M Crane; Kenneth A Tapia; Karina K Uldall; Sarah E Holte; Mari M Kitahata Journal: AIDS Patient Care STDS Date: 2008-03 Impact factor: 5.078
Authors: Judith A Cook; Dennis Grey; Jane Burke; Mardge H Cohen; Alejandra C Gurtman; Jean L Richardson; Tracey E Wilson; Mary A Young; Nancy A Hessol Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: P Todd Korthuis; Somnath Saha; John A Fleishman; Moriah McSharry McGrath; Joshua S Josephs; Richard D Moore; Kelly A Gebo; James Hellinger; Mary Catherine Beach Journal: J Gen Intern Med Date: 2008-10-02 Impact factor: 5.128
Authors: David B Hanna; Kate Buchacz; Kelly A Gebo; Nancy A Hessol; Michael A Horberg; Lisa P Jacobson; Gregory D Kirk; Mari M Kitahata; P Todd Korthuis; Richard D Moore; Sonia Napravnik; Pragna Patel; Michael J Silverberg; Timothy R Sterling; James H Willig; Ann Collier; Hasina Samji; Jennifer E Thorne; Keri N Althoff; Jeffrey N Martin; Benigno Rodriguez; Elizabeth A Stuart; Stephen J Gange Journal: PLoS One Date: 2013-11-18 Impact factor: 3.240